Skip to main content

Table 4 Median OS, HR and 95%CIs between intervention and contrast group

From: Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Authors (year) Combination group (95% CI)/months TACE alone group (95% CI)/months HR (95% CI)
Kudo et al. (2011) [15] 29.7 (28.6-NA) NA 1.06 (0.69–1.64)
Lencioni et al. (2012) [10] NA NA 0.898 (0.606–1.33)
Qu et al. (2012) [45] 27 (21.9–32.1) 17 (8.9–25.0) NA
Bai et al. (2013) [46] 7.5 5.1 0.61 (0.423–0.884)
Muhammad et al. (2013) [47] 20.6 (13.4–38.4) 18.3 (11.8–32.9) 0.82 (0.38–1.77)
Hu et al. (2014) [14] 7.0 4.9 0.63 (0.48–0.84)
Ohki et al. (2015) [6] 28.7 15.6 0.43 (0.24–0.76)
Yao et al. (2015) [12] 21.7 11.5 0.449 (0.302–0.668)
Wan et al.(2016) [50] 20.23 13.97 0.75 (0.61–0.94)
Zhang et al. (2016) [49] 14.9 (6.8–23.0) 6.1 (4.0–8.1) NA
Varghese et al. (2017) [13] BCLC-B = 16 (12.9–19.1) BCLC-B = 9 (6.3–11.7) BCLC-B:NA
BCLC-C = 9 (6.8–11.2) BCLC-C = 4(3–5) BCLC-C:NA
  1. Abbreviations: OS overall survival, HR hazard ratio, 95%CI 95% confidence intervals, NA not available
\